We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
12 own
18 watching
Current Price
$5.23
$0.08
(1.55%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
423.77M
52-Week High
14.73
52-Week Low
4
Average Volume
3.59M
Dividend Yield
--
P/E Ratio
21.0465
Market Capitalization423.77M
52-Week High14.73
52-Week Low4
Average Volume3.59M
Dividend Yield--
P/E Ratio21.0465
What does the Stockal+Disclaimer.pdf do?
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. The company is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
PR Newswire
1day ago
Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Nave Myelofibrosis Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Nave Myelofibrosis PR Newswire NEWTON, Mass., Dec. 5, 2022 Key Opinion...
PR Newswire
1day ago
Karyopharm Announces $165 Million Private Placement Karyopharm Announces $165 Million Private Placement PR Newswire NEWTON, Mass., Dec. 5, 2022 NEWTON, Mass., Dec. 5, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer...
Ticker Report
18days ago
Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI Get Rating) have been assigned an average recommendation of Moderate Buy from the nine brokerages that are presently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating ...
PR Newswire
4 months ago
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European...
CNW Group - News Releases
4 months ago
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$5.23
$0.08
(1.55%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00